Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating ocular diseases and conditions

A composition and eye disease technology, applied in chemical instruments and methods, diseases, metabolic diseases, etc., can solve problems such as affinity reduction

Active Publication Date: 2010-03-31
LPATH INC (US)
View PDF82 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even a single variable domain (or half of an Fv comprising only the three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, albeit at a lower affinity than the entire binding site

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating ocular diseases and conditions
  • Compositions and methods for treating ocular diseases and conditions
  • Compositions and methods for treating ocular diseases and conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0401] Embodiment 1: against the murine monoclonal antibody of S1P (Sphingomab TM ;LT1002)

[0402] One type of therapeutic antibody specifically binds undesired sphingolipids to achieve superior effects, such as (1) reducing the effective concentration of undesired toxic sphingolipids (and / or the concentration of their metabolite precursors), The sphingolipid promotes undesired effects such as cardiotoxicity, tumorigenicity, or angiogenic effects; (2) inhibits the binding of undesired, toxic, tumorigenic, or angiogenic sphingolipids to cell receptors, thus , and / or reduce the concentration of sphingolipids available for binding to such receptors. Examples of such therapeutic effects include, but are not limited to, the use of anti-S1P antibodies to reduce the effective in vivo serum concentration of available S1P, thereby blocking or at least limiting the tumorigenic and angiogenic effects of S1P, and its role in post-MI heart failure, cancer, or a role in fibrogenesi...

Embodiment 2

[0412] Example 2: ELISA assay

[0413] 1. Quantitative ELISA

[0414] Microtiter ELISA plates (Costar, Cat No. 3361) were coated with rabbit anti-mouse IgG and F(ab') was diluted in 1M carbonate buffer (pH 9.5) at 37°C 2 Fragment-specific antibody (Jackson, 315-005-047) 1 h. Plates were washed with PBS and blocked with PBS / BSA / Tween-20 for 1 h at 37°C. For the initial incubation, non-specific mouse IgG or human IgG, complete molecules (for calibration curves) and dilutions of the samples to be tested are added to the wells. Plates were washed and incubated with 100 μl per well of HRP-conjugated goat anti-mouse (H+L) (1 :40000 dilution) at 37°C (Jackson, cat No 115-035-146) for 1 h. After washing, the enzymatic reaction was detected using tetramethylbenzidine (Sigma, cat No T0440) and detected by adding 1M H 2 SO 4 termination. Optical density (OD) was measured at 450nm using a ThermoMultiskan EX. Raw data were converted into GraphPad software for analysis.

[0415]...

Embodiment 3

[0419] Example 3: SPHINGOMAB murine mAb is highly specific for S1P

[0420] A competitive ELISA confirmed the specificity of SPHINGOMAB for S1P compared to other bioactive lipids. SPHINGOMAB demonstrated no cross-reactivity to sphingosine (SPH), the immediate metabolic precursor of S1P or lysophosphatidic acid (LPA), an important extracellular signaling molecule similar in structure and function to S1P. SPHINGOMAB does not recognize other structurally similar lipids and metabolites, including ceramide-1-phosphate (C1P), dihydrosphingosine (DH-SPH), phosphatidylserine (PS), phosphatidylethanolamine (PE) or Sphingomyelin (SM). SPHINGOMAB does cross-react with dihydrosphingosine-1-phosphate (DH-S1P) and to a lesser extent with sphingosine phosphorylcholine (SPC) ( image 3 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and / or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1 -phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.

Description

[0001] related application [0002] This application claims Provisional Patent Application Serial No. 60 / 855,003, filed October 27, 2006 (Attorney Docket No. LPT-3020-PV), and Provisional Patent Application Serial No. 60 / 956,890, filed August 20, 2007 ( Attorney Docket No. LPT-3020-PV2), the entire contents of which are hereby incorporated by reference for any and all purposes. [0003] sequence listing [0004] This application is concurrently filed and includes a Sequence Listing, which was prepared and filed in accordance with applicable regulations and procedures. The Sequence Listing is hereby incorporated by reference for any and all purposes. technical field [0005] The present invention relates to preparations that bind to sphingosine-1-phosphate (S1P), in particular to humanized monoclonal antibodies, antibody fragments, and antibody derivatives that have specific reactivity with S1P under physiological conditions. Such formulations can be used to treat and / or pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C07K16/00C12P21/08A61K38/08
CPCC07K2317/92A61K38/08A61K2039/505A61K38/10C07K16/18C07K2317/56C07K2317/24A61P15/00A61P17/02A61P27/02A61P27/06A61P3/04A61P31/00A61P31/22A61P33/02A61P35/00A61P7/02A61P9/00A61P9/04A61P9/08A61P9/10
Inventor 罗格·A·萨巴迪尼威廉·A·加兰格伦·L·斯托勒
Owner LPATH INC (US)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com